<10           : 50–100% of normal dose
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAminoglycosides, clindamycin and polymyxins antagonise effects of neostigmine
ADMINISTRATION
Reconstition
–
Route
Neostigmine bromide: Oral Neostigmine metilsulfate: SC, IM, IV
Rate of Administration
IV: Very slowly
Comments
–
OTHER INFORMATION
Neostigmine 0.5 mg IV = 1–1.5 mg IM/SC =15 mg orallyWhen used for reversal of non- depolarising neuromuscular blockade, atropine (0.6–1.2 mg IV) or glycopyrronium should be given before or with neostigmine in order to prevent bradycardia, excessive salivation and other muscarinic actions of neostigmineThe physicochemical nature of neostigmine may tend to encourage its removal by various renal replacement therapies.